Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Understanding the Role of Uric Acid in Gout

Ruth Jessen Hickman, MD  |  Issue: September 2022  |  September 6, 2022

Lost and foundFrom the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening the way for successful treatment with urate-lowering therapies.1,2

Historical Background

Known to the Egyptians and the Greeks, gouty arthritis was one of the first diseases to be recognized as a distinct clinical entity. Dutch pioneer of microscopy Antonie van Leeuwenhoek was the first to describe the appearance of crystals from a gouty tophus in 1679, although the chemical composition was then unknown.3 In 1797, the English chemist William Hyde Wollaston, MD, demonstrated the presence of uric acid in gouty tophi, providing some of the earliest evidence of a possible pathophysiologic connection between high uric acid levels and gout.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Garrod’s Work

In 1854, English physician Alfred Baring Garrod, MD, described the famous thread test that he had developed—a semi-quantitative method for measuring the uric acid in blood or urine. Using it, he demonstrated that most of his gouty patients were hyperuricemic.1 Through research and his extensive clinical experience, Dr. Garrod came to believe that deposited urate crystals triggered the inflammation response in gouty inflammation.

Dr. Garrod

Dr. Garrod also carefully distinguished the characteristics of gout from rheumatoid arthritis—then termed rheumatism—arguing the two had distinct clinical presentations and underlying disease processes that did not morph into one another. In his mammoth 1876 treatise on the subject, Dr. Garrod noted the following as part of his key characterizations of gout:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Uric acid … is invariably present in the blood in abnormal quantities. … True gouty inflammation is always accompanied by a deposition of urate of soda in the inflamed part. … The deposit is crystalline and interstitial. … The deposited urate of soda may be looked upon as the cause, not the effect of the gouty inflammation. … In no disease but true gout is there a deposition of urate of soda in the inflamed tissues.4

However, many did not accept this explanation, and the clinicians of the time continued to debate gout’s cause. In 1899, a young Swiss internist, Max Freudweiler, MD, outlined the debate of the time. He noted that Garrod’s followers believed the oversaturation of body fluids led to the deposition of crystalline uric acid salts into the tissues.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutGout Resource CenterLost & FoundUric acid

Related Articles

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Gout, Glucose Metabolism and Obesity: A Case Review

    November 2, 2014

    New research explores association between hyperurecimia and gout with metabolic derangement

    Treating Asymptomatic Hyperuricemia Could Lower Risk of Developing Chronic Conditions

    August 12, 2016

    When uric acid becomes elevated in the human body, a variety of problems can develop, most notably gout—a painful, inflammatory arthritis caused by uric acid crystal deposition in joints. Chronically elevated uric acid can also lead to painful kidney stones. The majority of patients found to have hyperuricemia, however, never go on to develop gout…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences